As the spread of COVID-19 accelerates across the globe, everyone wants to find a way to tackle the pandemic, from Governments asking manufacturers to urgently make vital equipment to inventors creating innovative solutions. ...more
Today, on 20 March 2020, the Federal Constitutional Court in its decision on the Unified Patent Court ruled on the constitutional complaint against the law approving the agreement of 19 February 2013 on a Unified Patent Court...more
In the patent grant proceedings for two European Patent Applications, the EPO has ruled that an AI machine cannot be named as an inventor in a Patent Application. Doing so does not comply with the requirement to designate the...more
2/28/2020
/ Artificial Intelligence ,
EU ,
European Patent Office ,
Foreign Patent Applications ,
Intellectual Property Protection ,
Inventions ,
Inventors ,
Patent Applications ,
Patent Ownership ,
Patents ,
Statutory Requirements
MARKENRECHTSMODERNISIERUNGSGESETZ (MaMoG) ZUR UMSETZUNG DER EU-MARKENRECHTSLINIE 2015/2436 TRITT IN KRAFT -
Am 14. Januar 2019 trat die Novellierung des Markengesetzes durch das MaMoG in Kraft, mit der eine Reihe von...more
2/1/2019
/ Data Breach ,
Data Protection ,
E-Commerce ,
EU ,
European Union Intellectual Property Office (EUIPO) ,
General Data Protection Regulation (GDPR) ,
Germany ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Patents ,
Standard Essential Patents ,
Trademarks
Following the European Commission’s draft proposal for implementing the so-called SPC manufacturing waiver the Committee on Legal Affairs of the European Parliament published a draft report on presenting its suggested...more
1/15/2019
/ EU ,
European Commission ,
European Parliament ,
Generic Drugs ,
Intellectual Property Protection ,
Life Sciences ,
Manufacturers ,
Marketing Perspectives ,
Patent Expiration ,
Patent Infringement ,
Patents ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Supplementary Protection Certificate ,
Waivers
Increasing competition within Europe’s pharmaceutical space makes knowing the market and understanding available patent protections more critical than ever for both well established and new market players. Andreas von Falck...more
5/18/2018
/ Biotechnology ,
Compulsory Licenses ,
Doctrine of Equivalents ,
EU ,
Generic Drugs ,
Injunctions ,
Intellectual Property Protection ,
Inventions ,
Litigation Strategies ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Prescription Drugs ,
Technology Sector